Pulmonary arterial hypertension patient registry — Hospital Italiano de Buenos Aires
Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
This registry collects medical and heart‑lung test information from adults with pulmonary arterial hypertension treated at Hospital Italiano de Buenos Aires to follow their health and treatments over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 17 Years and up |
| Sex | All |
| Sponsor | Hospital Italiano de Buenos Aires Academic / other |
| Locations | 1 site (Buenos Aires, Buenos Aires) |
| Trial ID | NCT01501838 on ClinicalTrials.gov |
What this trial studies
The Institutional Registry at Hospital Italiano de Buenos Aires enrolls adults with WHO Group 1 pulmonary arterial hypertension using 2022 ESC/ERS hemodynamic criteria. It combines prospectively enrolled incident cases with prevalent HMO patients who were diagnosed before the registry began. Clinical, hemodynamic, treatment, and outcome data are recorded to characterize disease course and real‑world management. As an observational single‑center registry, it does not assign interventions but documents routine clinical care.
Who should consider this trial
Good fit: Adults (≥18 years) with WHO Group 1 pulmonary arterial hypertension who are entered in the Hospital Italiano de Buenos Aires institutional registry and meet the center's hemodynamic criteria.
Not a fit: Patients who had a lung transplant before baseline or who are not treated at Hospital Italiano de Buenos Aires (or do not meet the hemodynamic criteria) are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the registry could improve understanding of local disease patterns and treatment outcomes to help guide better care for patients with PAH.
How similar studies have performed: Other national and international PAH registries have successfully provided important epidemiologic and outcome data, so this approach is well established.
Eligibility criteria
Show full inclusion / exclusion criteria
* Inclusion Criteria: 1. Diagnosed with PAH WHO group 1 (2022 ESC/ESR guidelines criteria) as the presence of a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest with pulmonary arterial wedge pressure (PAWP) \>15 mmHg and pulmonary vascular resistance (PVR) \>2 WU, according to the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2. Included in the institutional registry of PAH of Hospital Italiano de Buenos Aires 3. Aged ≥18 years at the index date. * Exclusion Criteria History of lung transplantation surgery previously the baseline period
Where this trial is running
Buenos Aires, Buenos Aires
- Hospital Italiano de Buenos Aires — Buenos Aires, Buenos Aires, Argentina (Recruiting)
Study contacts
- Principal investigator: Ignacio M Bluro, MD — Hospital Italiano de Buenos Aires
- Study coordinator: Ignacio M Bluro, MD
- Email: ignacio.bluro@hospitalitaliano.org.ar
- Phone: +541149590200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.